SEC Comment Letter for AMEDISYS INC (AMED) (CIK 0000896262) — Dec 18, 2020
AMEDISYS INC (AMED) (CIK 0000896262)
Date: Dec. 18, 2020 · CIK: 0000896262 · Accession: 0000000000-20-012186
AI Filing Summary & Sentiment
File numbers found in text: 000-24260
Letter
United States securities and exchange commission logo December 18, 2020 Scott G. Ginn Chief Financial Officer Amedisys, Inc. 3854 American Way, Suite A Baton Rouge, LA 70816 Re:Amedisys, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed February 19, 2020 Definitive Proxy Statement on Schedule 14A Filed April 26, 2020 File No. 000-24260 Dear Mr. Ginn: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lori B. Metrock, Esq.
Show Raw Text
United States securities and exchange commission logo
December 18, 2020
Scott G. Ginn
Chief Financial Officer
Amedisys, Inc.
3854 American Way, Suite A
Baton Rouge, LA 70816
Re:Amedisys, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2019
Filed February 19, 2020
Definitive Proxy Statement on Schedule 14A
Filed April 26, 2020
File No. 000-24260
Dear Mr. Ginn:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Lori B. Metrock, Esq.